Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No one has anything to say?
This is sad.
looks like someone else bailed today.
But who is buying? And why?
Davey, was the new group truthful about going forward with this company? Seems to me they can't raise enough interest.
Next to getting married, buying this stock was the worst mistake of my life.
I think you should add the ex-BOD board meetings.
Here is a clip of the last one.
stoll video poker
We are back to normal.
Any of you guys hear anything?
Ya! Amp up for an evening of smart sex!
The marketing potential is huge!
Anyone have any thoughts about the volume.
We are consistently trading in the folding money range.
No more $5.00 days. Interesting...
I agree.
You picked up on my sarcasm. Or did you?
If he runs it like a start up gold mining operation we should see $1.00 before long.
No biotech experience.
It is definitely a plus. A businessman who knows how to run a business. We do have something to look forward too.
Davey,
Thanks for the update, but what is the game plan from here?
Any insight on the application direction. ADHD, SA,etc?
I agree. Koreans trying to take over on the cheap?
Is this why the Koreans might have lent the money to Cortex?
Neurosci Lett. 2012 Dec 7;531(2):193-7. doi: 10.1016/j.neulet.2012.10.020. Epub 2012 Oct 26.
LY404187, a potentiator of AMPARs, enhances both the amplitude and 1/CV2 of AMPA EPSCs but not NMDA EPSCs at CA3-CA1 synapses in the hippocampus of neonatal rats.
Song B, Lee S, Choi S.
Source
School of Biological Sciences, College of Natural Sciences, Seoul National University, Seoul 151-742, Republic of Korea.
Abstract
Cyclothiazide is a well-known AMPAR potentiator, but it has also been shown to enhance the probability of presynaptic release in some cases. Interestingly, cyclothiazide has been shown to reveal AMPA EPSCs at silent CA3-CA1 synapses (which exhibit NMDA EPSCs but not AMPA EPSCs) in the hippocampus of neonatal or developing rats, but this particular result has not been reproduced at other types of synapses. Although this discrepancy may be due to the different mechanisms underlying silent synapses in distinct brain subregions, it is also possible that cyclothiazide has pre- and postsynaptic molecular targets that are differentially expressed at the different types (or different developing stages) of synapses. In this study, we reexamined, using a new AMPAR potentiator, LY404187, whether AMPAR potentiation leads to the conversion of silent CA3-CA1 synapses into functional synapses (exhibiting both AMPA and NMDA EPSCs) in the hippocampus of neonatal rats. LY404187 did not appear to alter the probability of presynaptic release, as evidenced by the lack of significant changes in both the amplitude and the paired-pulse facilitation ratio (an index of release probability) of NMDA EPSCs. LY404187 enhanced both the amplitude and 1/CV(2) (CV: coefficient of variation) of AMPA EPSCs but not NMDA EPSCs. Because an increase in 1/CV(2) reflects an increased number of functional synapses and/or an enhanced release probability, the LY404187-induced increase in the 1/CV(2) value of AMPA EPSCs, but not NMDA EPSCs, likely indicates an increased number of synapses exhibiting AMPA EPSCs but not an increased number of synapses exhibiting NMDA EPSCs. Because AMPARs and NMDARs are co-localized at the same synapses, our findings are consistent with a scenario in which LY404187 enables silent synapses to acquire AMPA EPSCs.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
PMID:
23103715
[PubMed - in process]
http://bestnootropic.org/ampakines/http://bestnootropic.org/ampakines/" rel="nofollow" target="_blank" >http://bestnootropic.org/ampakines/
A very interesting article!
www.musbed.com/tr/DergiPdf/8f86821e8f024ebeba40903faf307af5.pdf[tag]Ampakines: Selective AMPA Receptor Modulators
with Potential Benefits[/tag]
New directions in the treatment of autism spectrum disorders from animal model research
May 2012, Vol. 7, No. 5 , Pages 407-416 (doi:10.1517/17460441.2012.678828)
HTML
PDF (224 KB)
PDF Plus (224 KB)
Reprints
Permissions
Kathryn K Chadman †1 PhD, Sara R Guariglia2 PhD Advanced Imaging Facility Manager/Neuroscience Research Associate & Jiyeon Helen Yoo1
1 New York State Institute for Basic Research in Developmental Disabilities,
1050 Forest Hill Road, Staten Island, NY 10314
, USA +1 718 494 5364; +1 718 494 5296; kathryn.chadman@opwdd.ny.gov
2 CUNY College of Staten Island,
2800 Victory Blvd., Staten Island, NY 10314
, USA
†Author for correspondence
Introduction: Currently, there is not an effective pharmacotherapy for the core symptoms of the autism spectrum disorders (ASD), which include aberrant social behavior, delayed communication and repetitive behavior and/or restricted interests. There are several drugs that treat the symptoms associated with autism including irritability, aggressiveness and hyperactivity. Current drug research is based on the ongoing genetic, animal model and neuropathologic research. Two areas in particular, the glutamate and oxytocin systems, provide exciting new avenues for drug discovery.
Areas covered: This review examines what approaches have been used for the drugs that are currently being used to treat people with ASD. For the most part, drugs that treat other neuropsychiatric disorders have been examined to treat the people with ASD, unfortunately with little effect on the core symptoms.
Expert Opinion: Until recently, there was not a plethora of knowledge about the neurobiological substrates of social behavior, pragmatic language usage and repetitive and/or restricted behaviors. Therefore, drug discovery has used the tools available for other neuropsychiatric disorders. Now that more biological information is available, there are many avenues for research for drug targets for ASD.
Keywords
ABA, autism, glutamate, mouse model, oxytocin, pharmacology
Read More: http://informahealthcare.com/doi/abs/10.1517/17460441.2012.678828
Nicely put, and very true.
I think Varney camped the intellectual property here to prevent a theft at discount prices. Anyone else agree.
Maybe there is one more lucky coin left to put into the machine!
Spin baby! Spin!
The volume continues to remain pathetic.
Now that all of the old timers are gone, can we assume they sucked all of the life out of this crap, leaving nothing but a burned trail of empty booze bottles, used up hookers, and quarter wrappers from the wasted coins dumped into video poker games!
I hope you are right. It's been a long time since this stock has had any positive momentum. I would love to see a .25 again.
It's possible we may see something about the office in Irvine closing to consolidate with the pot heads. Just a guess.
nothing is the right choice of words!
This is virtual garbage.
Mark Varney hasn't communicated with us for months.
I really believe this is now a virtual company.
Can anyone prove otherwise?
I feel Mark Varney owes us a little communication.
He doesn't have to tell us any more then, I am still going to work everyday, and I am making every effort to succeed.
Buy APPA, get some money back.
I didn't ask him to reveal any secrets, just let us know if he feels confident about a future for the companies investors.
You know, something like, We are discussing various options, with several companies.
Davey,
I sent him an email. I simply asked him to do the right thing and communicate with us (the bag holders). No response!
He's too busy with him immediate needs. Not ours.
I can't get over the massive volume we have been experiencing.
Cortex is rocking!
GFP
The AP Pharma team addressed all of the fda concerns. Read the new corporate presentation. The number of shares is a concern, but the message and direction of this management team is clear.
(Unlike Cortex)
After the validation of the delivery system, take existing approved drugs and improve them. Fast and easy. But approval needs to happen first. Think about it, one dose, slow release, for up to 2 weeks. Pretty cool! Price target short term $2.00, long term who knows.
Just in case anyone is interested, APPA is beginning it run. Closed at .70 today, expect big things. This is not just a new drug approval, it's the validation of a new nano technology delivery system that can be used with many different already approved drugs used in pain management. This is not hype, do your own DD. GFP turned me on to this in 2010. He sold, I didn't.
It will get my cor loses back for me, I hope...
Food4thought,
I feel your pain. I also echo your thought process. It was very unwise to dump as much as we did on this stock. My losses are 110K, and like you had mentally spent my share of the profits on early retirement.
I still hold hope of some kind of recovery. You never know...
With that off of my chest, from down here in Chicago land I hope the Packers kick ass! Love their style.
I am however, once again a bear fan thanks to the firing of Lovie!
Good for him. Add up the losses from this board and my guess is he did ok over the past 5 years. Why should any of the cortex management get a pass for failure. Will the Jets get a pass from the NY fans. Why should I feel sorry for him? I understand your loyalty to Cor since you were privy to direct contact, but I feel let down because Coleman couldn't get us into Ph2 or Ph3. He was the money man, right? As far as Varney is concerned, he has earned my respect. He is playing a bad hand that was dealt to him by Stoll, and Coleman.
Davey, hows your buddy Jim Coleman doing. Hope he knows his lack of business development threw this company off of the cliff.
He probably is retiring on a beach spending what he could get from the video poker fund.
$110,000
They tested it on rats! Why not themselves. They have been drunken fools for the past 8 years.